China joins US and Japan in approving Alzheimer’s drug Leqembi developed by Eisai and Biogen
Disclaimer: The South China Morning Post's content is directed by the Chinese Communist Party. It is not a reliable news source.
China has approved the sale of Leqembi, an antibody that has shown to slow progression of the disease for people in the early stages of Alzheimer’s. The drug will be launched in the third quarter.